See the latest news and media coverage for SpectraCure. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of photodynamic treatment systems for prostate cancer
spectracure.comLast updated
In short: SpectraCure secured key patents in China and Canada, progressed clinical studies for prostate cancer, and completed a rights issue.
It protects the unique optical fiber technology that combines measurement and treatment in the Q-PRO® system. The approval follows previous acceptance in Europe and Japan, with ongoing reviews in other key markets.
Canada is the last country where SpectraCure's patent application for IDOSE technology has been granted, following approvals in the USA, Europe, China and Japan.
Guarantee commitments of 24.4 percent are utilized and the company is provided with approximately SEK 25.7 million before costs. Final outcome is expected on August 6, 2026.
The proceeds will finance the completion of phase 2, the primary study, as well as preparations for phase 3.
Financial cash flow amounted to -0.690 in the last quarter, representing a change of -105.566% compared to the previous quarter...
SpectraCure AB has published its financial results for the second quarter and the first half-year ended June 30, 2026. For the second quarter, the...
SpectraCure's rights issue of units was subscribed to 75% including guarantee commitments. Emissionsguiden raises three retroactive flags.
The medical technology company SpectraCure has released the memorandum for its rights issue of SEK 34 million and Emissionsguiden raises a new flag for insufficient information.
Track SpectraCure and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to SpectraCure and other trending companies.